版本:
中国

BRIEF-Aerie pharmaceuticals updates full-year 2016 cash burn guidance

Sept 22 Aerie Pharmaceuticals Inc

* Expects cash and cash equivalents to total approximately $230 million as of December 31, 2016

* Updated full-year 2016 cash burn guidance to approximately $85 million, an increase from previous guidance of $75 million

* Updated guidance reflects initiatives like start-up of clinical trials in Japan, construction of manufacturing plant in Ireland Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐